Izba (Travoprost)

Travoprost mimics prostaglandin F2α and binds to FP receptors in the eye’s ciliary muscle. This activation enhances the uveoscleral outflow pathway, allowing aqueous humor to drain more efficiently from the anterior chamber, thereby decreasing intra‑ocular pressure.

The prescribed dose of Izba is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact regimen should follow the prescriber’s instructions and may be adjusted based on individual response.

Safety of Travoprost in pregnancy or while nursing has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Izba (Travoprost) belongs to the prostaglandin analog class, which generally offers once‑daily dosing and a strong IOP‑lowering effect. Compared with beta‑blocker drops, prostaglandin analogs often have a more pronounced pressure reduction and a different side‑effect profile, such as changes in eyelash growth and iris color.

Store Izba at room temperature, preferably below 25 °C. Keep the bottle in its original packaging, protect it from direct light and moisture, and ensure the cap is tightly closed to maintain sterility and potency.

Izba is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, usually in the evening. The patient should wash hands before use, avoid touching the tip of the bottle to the eye or any surface, and wait a few minutes before applying other eye medications.

Serious risks, though rare, include severe allergic reactions, significant ocular inflammation (such as uveitis or iritis), and sudden loss of vision. Patients should seek immediate medical attention if they experience intense eye pain, swelling, redness, or any rapid change in vision.

Izba should not be used by individuals with known hypersensitivity to Travoprost or any component of the formulation, and it is contraindicated in eyes with active intra‑ocular inflammation or infection. Caution is also advised for patients with a history of asthma or severe ocular surface disease.